Boehringer selects lead candidate for Alzheimer’s

pharmafile | May 24, 2010 | News story | Research and Development Ablynx, Boehringer 

Boehringer Ingelheim has selected a lead candidate for further development to treat Alzheimer’s disease from its collaboration with Ablynx.

Belgium-based Ablynx specialises in the discovery and development of a novel class of therapeutic proteins based on single-domain antibody fragments it calls Nanobodies.

The selection of the candidate is very good news for Ablynx, as it is the first lead candidate emerging from the Alzheimer’s disease collaboration between the partners, and will result in a two million euros milestone payment to Ablynx.

The companies began their collaboration in January 2007, focusing on the discovery and development of new therapies for Alzheimer’s disease using Ablynx’s Nanobodies.

Advertisement

The deal is worth a possible $265 million in milestone payments plus undisclosed royalties. Boehringer Ingelheim will be solely responsible for the development, manufacture and commercialisation of any products resulting from the research collaboration.

“Ablynx’s delivery of this potentially ‘first-in-class’ Nanobody candidate for the treatment of Alzheimer’s disease highlights the speed at which we progressed from initiation of the discovery programme in 2007 to this stage of development for a very challenging target”, said Dr Edwin Moses, chief executive and chairman of Ablynx.

Andrew McConaghie

Related Content

heart-2372134_640

Lilly and Boehringer’s Jardiance reduces hospitalisation and CV death risk from heart failure at Phase 3

Boehringer Ingelheim and Eli Lilly have announced strong Phase 3 news on their sodium-glucose co-transporter-2 …

shutterstock_138095450

Boehringer withdraws its £700m investment in Hikma Pharmaceuticals

Boehringer has revealed that it intends to withdraw its investment from Hikma Pharmaceuticals, with the …

boehringer_biberach_germany_copy

Boehringer’s TKI inhibitor Ofev gets FDA approval for chronic fibrosing interstitial lung diseases with a progressive phenotype

The FDA has green-lit Boehringer Ingelheim’s multi-targeted tyrosine kinase inhibitor Ofev (nintedanib) in the treatment …

The Gateway to Local Adoption Series

Latest content